Login to Your Account



Other News To Note


Friday, October 14, 2011
Sangamo BioSciences Inc., of Richmond, Calif., said a preclinical study demonstrated the highly specific, functional correction of the alpha 1-antitrypsin gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases (ZFN). The study, published in the Oct. 12, 2011, online issue of Nature, highlighted the potential of combining human iPSCs with ZFN-driven gene correction to generate differentiated cell-based therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription